Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bvd-523
2. Vrt752271
1. 869886-67-9
2. Vrt752271
3. Bvd-523
4. Ulixertinib [inn]
5. Ulixertinib (bvd-523)
6. Bvd-erk
7. 16zdh50o1u
8. Chembl3590106
9. Ulixertinib (inn)
10. 869886-67-9 (free Base)
11. Vrt-752271
12. Ulixertinib (bvd-523, Vrt752271)
13. 1h-pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-n-((1s)-1-(3-chlorophenyl)-2-hydroxyethyl)-
14. N-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide
15. (s)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-(1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide
16. (s)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-(1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide.
17. 4-[5-chloranyl-2-(propan-2-ylamino)pyridin-4-yl]-~{n}-[(1~{s})-1-(3-chlorophenyl)-2-oxidanyl-ethyl]-1~{h}-pyrrole-2-carboxamide
18. Unii-16zdh50o1u
19. Ulixertinib (bvd-523,vrt752271)
20. 4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-n-((s)-1-(3-chlorophenyl)-2-hydroxyethyl)-1h-pyrrole-2-carboxamide
21. Bvd523 Hcl
22. Bvd-523 Hcl
23. Ulixertinib [who-dd]
24. Vrt752271 Hcl
25. Gtpl9210
26. Schembl14211742
27. Dtxsid601025683
28. Bcp04232
29. Ex-a1332
30. Bdbm50094465
31. Nsc797771
32. Nsc800959
33. S7854
34. Zinc34642570
35. Akos025396467
36. Ccg-269049
37. Db13930
38. Nsc-797771
39. Nsc-800959
40. Ncgc00378692-02
41. Ncgc00378692-05
42. Ncgc00378692-07
43. Ac-33165
44. As-56114
45. Hy-15816
46. Bcp0726000085
47. D11038
48. J-690368
49. Q27089081
50. 3,5-dichloro-2-hydroxy-n-(4-methoxy-3-biphenylyl)benzenesulfonamide
51. 4-[5-chloro-2-(isopropylamino)-4-pyridinyl]-n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-1h-pyrrole-2-carboxamide
| Molecular Weight | 433.3 g/mol |
|---|---|
| Molecular Formula | C21H22Cl2N4O2 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | 432.1119813 g/mol |
| Monoisotopic Mass | 432.1119813 g/mol |
| Topological Polar Surface Area | 90 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 539 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Ulixertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ulixertinib, including repackagers and relabelers. The FDA regulates Ulixertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ulixertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ulixertinib supplier is an individual or a company that provides Ulixertinib active pharmaceutical ingredient (API) or Ulixertinib finished formulations upon request. The Ulixertinib suppliers may include Ulixertinib API manufacturers, exporters, distributors and traders.
Ulixertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ulixertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ulixertinib GMP manufacturer or Ulixertinib GMP API supplier for your needs.
A Ulixertinib CoA (Certificate of Analysis) is a formal document that attests to Ulixertinib's compliance with Ulixertinib specifications and serves as a tool for batch-level quality control.
Ulixertinib CoA mostly includes findings from lab analyses of a specific batch. For each Ulixertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ulixertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ulixertinib EP), Ulixertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ulixertinib USP).
LOOKING FOR A SUPPLIER?
